↓ Skip to main content

Dove Medical Press

Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction

Overview of attention for article published in Infection and Drug Resistance, July 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
84 Mendeley
Title
Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction
Published in
Infection and Drug Resistance, July 2018
DOI 10.2147/idr.s170337
Pubmed ID
Authors

Laura C García-Carnero, Luis A Pérez-García, José A Martínez-Álvarez, Juana E Reyes-Martínez, Héctor M Mora-Montes

Abstract

Human fungal infections remain a major challenge in medicine. Only a limited number of antifungal drugs are available, which are often related to severe adverse effects. In addition, there is an increased emergence related to resistant strains, which makes imperative to understand the host-pathogen interactions as well as to develop alternative treatments. Host innate and adaptive immunity play a crucial role controlling fungal infections; therefore, vaccines are a viable tool to prevent and treat fungal pathogens. Innate immunity is triggered by the interaction between the cell surface pattern recognition receptors (PRRs) and the pathogen-associated molecular patterns (PAMPs). Such an initial immunological response is yet little understood in fungal infections, in part due to the complexity and plasticity of the fungal cell walls. Described host cell-fungus interactions and antigenic molecules are addressed in this paper. Furthermore, antigens found in the cell wall and capsule, including peptides, glycoproteins, glycolipids, and glycans, have been used to trigger specific immune responses, and an increased production of antibodies has been observed when attached to immunogenic molecules. The recent biotechnological advances have allowed the development of vaccines against viral and bacterial pathogens with positive results; therefore, this technology has been applied to develop anti-fungal vaccines. Passive immunization has also emerged as an appealing alternative to treat disseminated mycosis, especially in immunocompromised patients. Those approaches have a long way to be seen in clinical cases. However, all studies discussed here open the possibility to have access to new therapies to be applied alone or in combination with current antifungal drugs. Herein, the state of the art of fungal vaccine developments is discussed in this review, highlighting new advances against Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans, Paracoccidioides brasiliensis, and Sporothrix spp.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 84 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 18%
Student > Bachelor 15 18%
Student > Master 8 10%
Researcher 6 7%
Professor 5 6%
Other 14 17%
Unknown 21 25%
Readers by discipline Count As %
Immunology and Microbiology 17 20%
Biochemistry, Genetics and Molecular Biology 15 18%
Medicine and Dentistry 8 10%
Agricultural and Biological Sciences 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 8 10%
Unknown 26 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2018.
All research outputs
#13,044,672
of 23,096,849 outputs
Outputs from Infection and Drug Resistance
#362
of 1,698 outputs
Outputs of similar age
#157,817
of 328,121 outputs
Outputs of similar age from Infection and Drug Resistance
#9
of 41 outputs
Altmetric has tracked 23,096,849 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,698 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,121 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.